Analysis Shows IORT Boost Effective Prior to Whole Breast Radiation

January 5, 2017 — iCAD Inc. announced that researchers presented updated data on the use of intraoperative radiation therapy (IORT) with the Xoft Axxent Electronic Brachytherapy (eBx) System during the San Antonio Breast Cancer Symposium (SABCS), Dec. 6-10 in San Antonio, Texas. The data include results from a subset of patients who received IORT with the Xoft System as a boost prior to administration of whole breast radiation therapy (WBRT) in patients with early-stage breast cancer.

At the meeting, research was presented by Alam M. Nisar Syed, M.D., medical director, radiation oncology and endocurietherapy, Memorial Care Cancer Institute, Long Beach Memorial Medical Center. Syed’s findings include updated data on the treatment of 898 patients with early-stage breast cancer using IORT with the Xoft System at 26 hospitals in the United States and Portugal. The findings show that 90 percent of patients had excellent-to-good cosmesis with low rates of high-grade adverse events and recurrences two years post-treatment with Xoft IORT.

Of these 898 patients, 44 presented additional risk factors and were subsequently treated with WBRT, thus receiving an IORT boost dose prior to conventional treatment. This subset of patients was reviewed independently from the primary study, and Syed said he will continue to follow them as a separate subset for the duration of the 10-year study. The findings thus far show that IORT using the Xoft System as a tumor-bed boost at the time of lumpectomy is safe, with low morbidity, excellent-to-good cosmetic results and mostly low-grade adverse events.

“By identifying a subset of boost patients, our multi-center study not only showed positive clinical results, it highlighted the Xoft System’s versatility in the treatment of early-stage breast cancer,” said Syed. “IORT with the Xoft System offers patients many advantages, whether administered as monotherapy for smaller tumors or as a boost for women who require further treatment due to additional risk factors.”

For more information: www.xoftinc.com